Tango Therapeutics (TNGX) Other Non Operating Income (2020 - 2026)

Tango Therapeutics' Other Non Operating Income history runs 7 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• On a quarterly basis, Other Non Operating Income changed 0.47% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $4.1 million, a 37.33% decrease from a year earlier, with the FY2025 full-year figure at $4.1 million, down 46.54% from the prior year.
• Other Non Operating Income fell to $1.1 million in Q1 2026 per TNGX's latest filing, from $1.4 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $2.2 million in Q1 2024 and bottomed at -$47000.0 in Q1 2022.
• The 5-year median for Other Non Operating Income is $1.2 million (2023), against an average of $1.2 million.
• Across the five-year window, Other Non Operating Income soared 2689.36% in 2023 and plunged 63.96% in 2025, its largest moves.
• Year by year, Other Non Operating Income stood at $967000.0 in 2022, then jumped by 113.13% to $2.1 million in 2023, then retreated by 28.38% to $1.5 million in 2024, then slipped by 6.5% to $1.4 million in 2025, then dropped by 21.81% to $1.1 million in 2026.
• Per Business Quant, the three latest TNGX Other Non Operating Income figures stand at $1.1 million (Q1 2026), $1.4 million (Q4 2025), and $705000.0 (Q3 2025).